Brokerages Set AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) PT at $2.40

Share on StockTwits

Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have been given a consensus rating of “Hold” by the nine ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $2.55.

Several research firms have recently weighed in on AVEO. Piper Jaffray Companies lifted their price objective on AVEO Pharmaceuticals from $3.00 to $4.00 and gave the company an “overweight” rating in a report on Tuesday, September 10th. HC Wainwright upgraded AVEO Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $1.00 to $1.75 in a report on Wednesday.

Several large investors have recently added to or reduced their stakes in AVEO. HCR Wealth Advisors bought a new position in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $28,000. Anson Funds Management LP bought a new position in shares of AVEO Pharmaceuticals during the 2nd quarter valued at about $33,000. Cetera Advisor Networks LLC bought a new position in shares of AVEO Pharmaceuticals during the 2nd quarter valued at about $38,000. SG Americas Securities LLC bought a new position in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $50,000. Finally, Jane Street Group LLC bought a new position in shares of AVEO Pharmaceuticals during the 2nd quarter valued at about $98,000. Institutional investors and hedge funds own 29.55% of the company’s stock.

AVEO Pharmaceuticals stock opened at $0.94 on Tuesday. The firm has a market capitalization of $147.69 million, a P/E ratio of -4.93 and a beta of 0.74. AVEO Pharmaceuticals has a 1 year low of $0.49 and a 1 year high of $3.59. The business has a 50-day moving average of $0.69 and a 200-day moving average of $0.75. The company has a current ratio of 2.21, a quick ratio of 2.21 and a debt-to-equity ratio of 6.84.

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.04. The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.78 million. AVEO Pharmaceuticals had a negative return on equity of 50.69% and a negative net margin of 46.69%. Research analysts anticipate that AVEO Pharmaceuticals will post -0.08 EPS for the current fiscal year.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: Market Capitalization

Analyst Recommendations for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ubex  Price Hits $0.0004
Ubex Price Hits $0.0004
Maximine Coin 1-Day Trading Volume Tops $43,578.00
Maximine Coin 1-Day Trading Volume Tops $43,578.00
Coupa Software Inc  Expected to Announce Quarterly Sales of $96.52 Million
Coupa Software Inc Expected to Announce Quarterly Sales of $96.52 Million
PAXEX  Price Tops $0.0002
PAXEX Price Tops $0.0002
ZCore One Day Trading Volume Tops $1,202.00
ZCore One Day Trading Volume Tops $1,202.00
Brokerages Set $67.00 Target Price for Neenah Inc
Brokerages Set $67.00 Target Price for Neenah Inc


© 2006-2019 Ticker Report